SPRAVATO®: Through the eyes of the patients
What experiences have patients and healthcare professionals (HCPs) had of using SPRAVATO®?
Dr. Wieslaw Jerzy Cubala
For more information please see the HCP-patient discussion guide here, alongside other supporting materials.
This animation has been created using direct quotes from both patients and healthcare professionals in the treatment-resistant depression (TRD) clinical trials for SPRAVATO®.* It has been designed for HCPs to watch ahead of prescribing SPRAVATO® to their patients. Additional information can be found in the Janssen Medical CloudTM Toolkit website. Please note that the experiences of individual patients and HCPs may differ from those shown in the animation.
Learn more about what makes SPRAVATO® a breakthrough therapy*[1][2]
Connect with peers who have SPRAVATO® prescribing experience.
Access live and recorded meetings
These videos reflect the experiences, ideas and opinions of those featured within them, not necessarily those of Janssen. As such, all content is solely for explanatory purpose, and does not represent any specific recommendation or guidance.
* Interviews conducted with clinical trialists treating patients with TRD; defined as patients with Major Depressive Disorder who have not responded to two or more antidepressants in the current depressive episode.[3]
** Following the approval of the SSRI fluoxetine in 1987, approved treatments have continued to primarily target the monoaminergic system.[4][5] In contrast, SPRAVATO® is an antagonist of the NMDA glutamate receptor.[3]
Abbreviations
HCP, healthcare professional; NMDA, N-methyl-D-aspartate; SSRI, selective serotonin reuptake inhibitor; TRD, treatment-resistant depression.
[Insert local AE reporting text as required]
[Insert link to PI]
[Request information from the Janssen Medical Information team]
[Contact your Janssen Account Manager or Medical Scientific Liaison Manager]
